While the RB1 gene is rarely altered in these cancers, the RB1 protein is disabled by cyclin E, CDK2 and/or CDK4/6 upregulation as well as by loss of the CDK inhibitors, p27 and p16INK4a, in essentially all MPNSTs [11,20,21]. This evidence concerns the gene CDK2 and cancer.